Adjuvant immunotherapies in RCC based on data from KEYNOTE-564
Maria Bourlon, MD, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico discusses adjuvant immunotherapies in patients with clear cell renal cell carcinoma (ccRCC). After a partial or radical nephrectomy, patients with intermediate to high risk are vulnerable to recurrence. Data from the KEYNOTE-564 (NCT03142334) study show an overall survival (OS) advantage in patients treated with pembrolizumab, with localised control, metastasectomy and no evidence of disease after 1 year. However, treatment options after progressing on pembrolizumab depends on when failure occurs; patients may benefit from tyrosine kinase inhibitors (TKIs), belzutifan or enrolment into specific clinical trials, but failure after a significant time period causes speculation around whether immunotherapy is still the best option. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
